Abstract
Although thrombolysis with tissue plasminogen activator (tPA) is a stroke therapy approved by the US Food and Drug Administration, its efficacy may be limited by neurotoxic side effects1,2. Recently, proteolytic damage involving matrix metalloproteinases (MMPs) have been implicated. In experimental embolic stroke models, MMP inhibitors decreased cerebral hemorrhage and injury after treatment with tPA3,4. MMPs comprise a family of zinc endopeptidases that can modify several components of the extracellular matrix5,6. In particular, the gelatinases MMP-2 and MMP-9 can degrade neurovascular matrix integrity. MMP-9 promotes neuronal death by disrupting cell-matrix interactions7, and MMP-9 knockout mice have reduced blood-brain barrier leakage and infarction after cerebral ischemia8. Hence it is possible that tPA upregulates MMPs in the brain, and that subsequent matrix degradation causes brain injury. Here we show that tPA upregulates MMP-9 in cell culture and in vivo. MMP-9 levels were lower in tPA knockouts compared with wild-type mice after focal cerebral ischemia. In human cerebral microvascular endothelial cells, MMP-9 was upregulated when recombinant tPA was added. RNA interference (RNAi) suggested that this response was mediated by the low-density lipoprotein receptor–related protein (LRP), which avidly binds tPA9 and possesses signaling properties10. Targeting the tPA-LRP signaling pathway in brain may offer new approaches for decreasing neurotoxicity and improving stroke therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
del Zoppo, G.J. tPA: a neuron buster too? Nat. Med. 4, 148–150 (1998).
Hacke, W. et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53 (suppl. 4), S3–S15 (1999).
Lapchak, P.A., Chapman, D.F. & Zivin, J.A. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31, 3034–3040 (2000).
Sumii, T. & Lo, E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33, 831–836 (2002).
Yong, V.W., Power, C., Forsyth, P. & Edwards, D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2, 502–511 (2001).
Lo, E.H., Wang, X. & Cuzner, M.L. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. 69, 1–9 (2002).
Gu, Z. et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186–1190 (2002).
Asahi, M. et al. Effects of matrix metalloproteinase 9 gene knockout on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724–7732 (2001).
Zhuo, M. et al. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J. Neurosci. 20, 542–549 (2000).
Herz, J. & Strickland, D.K. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108, 779–784 (2001).
Fini, M.E., Cook, J.R., Mohan, R. & Brinckerhoff, C.E. Regulation of matrix metalloproteinase gene expression in Matrix Metalloproteinases (eds. Parks, W.C. & Mecham, R.P.) 299–356 (Academic Press, New York, 1998).
Nicole, O. et al. The proteolytic activity of tissue plasminogen activator enhances NMDA receptor mediated signaling. Nat. Med. 7, 59–64 (2001).
Cuzner, M.L. & Opdenakker, G. Plasminogen activators and matrix metalloproteinases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94, 1–14 (1999).
Koenig, H., Trout, J.J., Goldstone, A.D. & Lu, C. Capillary NMDA receptors regulate blood-brain barrier function and breakdown. Brain Res. 588, 297–303 (1992).
Hiltunen, T.P., Luoma, J.S., Nikkari, T. & Yla-Herttuala, S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 97, 1079–1086 (1998).
Qiu, Z., Strickland, D.K., Hyman, B.T. & Rebeck, G.W. Alpha 2-macroglobulin exposure reduces calcium responses to N-methyl-D-aspartate via low density lipoprotein receptor-related protein in cultured hippocampal neurons. J. Biol. Chem. 277, 14458–14466 (2002).
Brummelkamp, T.R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553 (2002).
Bacskai, B.J., Xia, M.Q., Strickland, D.K., Rebeck, G.W. & Hyman, B.T. The endocytic receptor protein LRP also mediates neuronal calcium signaling via NMDA receptors. Proc. Natl. Acad. Sci. USA 97, 11551–11556 (2000).
Montaner, J. et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107, 598–603 (2003).
Gotthard, M. et al. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biologic functions in cell communication and signal transduction. J. Biol. Chem. 275, 25616–25624 (2000).
Liacini, A., Sylvester, J., Li, W.Q. & Zafarullah, M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 21, 251–262 (2002).
Wang, X., Mori, T., Jung, J., Fini, M.E. & Lo, E.H. Secretion of matrix metalloproteinase-2 and -9 following traumatic injury in rat cortical cultures and involvement of MAP kinase. J. Neurotrauma 19, 615–625 (2002).
Hahn-Dantona, E., Ruiz, J.F., Bornstein, P. & Strickland, D.K. The low density lipoprotein receptor-related protein modulates levels of MMP-9. J. Biol. Chem. 276, 15498–15503 (2001).
Lo, E.H., Dalkara, T. & Moskowitz, M.A. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 4, 399–415 (2003).
Mataga, N., Nagai, N. & Hensch, T.K. Permissive proteolytic activity for visual cortical plasticity. Proc. Natl. Acad. Sci. USA 99, 7717–7721 (2002).
Tsirka, S.E., Rogove, A.D. & Strickland, S. Neuronal cell death and TPA. Nature 384, 123–124 (1996).
Wang, Y.F. et al. TPA increases neuronal damage after focal cerebral ischemia in wild type and TPA-deficient mice. Nat. Med. 4, 228–231 (1998).
Nagai, N. et al. Tissue type plasminogen activator is involved in the process of neuronal death induced by oxygen-glucose deprivation. J. Cereb. Blood Flow Metab. 21, 631–634 (2001).
Acknowledgements
This work was supported in part by National Institute of Neurological Disorders and Stroke grants R01-NS37074, R01-NS38731, R01-NS40529, R01-AG14473 and P50-NS10828. We thank R. Zhu and J. Bai for assistance with RNAi experiments, and J.-C. Jung for helpful discussions on mRNA measurement.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Wang, X., Lee, SR., Arai, K. et al. Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9, 1313–1317 (2003). https://doi.org/10.1038/nm926
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm926